Eprenetapopt in combination with azacitidine failed to achieve the primary outcome in a phase 3 trial of TP53-mutant myelodysplastic syndrome (MDS), and magrolimab in combination with venetoclax and azacitidine was discontinued in phase 3 trials for both MDS and AML [65,66]. This evidence concerns the gene TP53 and myelodysplastic syndrome.